TACSTD2 and breast carcinoma: To further demonstrate the broad applicability of this therapy, we utilized TROP2 as a tumor antigen, which is highly expressed in triple-negative and luminal breast cancers [23], to construct the ‘αTROP2-DPP4’ fusion protein.